Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
17
10
2018
accepted:
20
02
2019
pubmed:
19
3
2019
medline:
24
7
2020
entrez:
19
3
2019
Statut:
epublish
Résumé
Treatment of
Identifiants
pubmed: 30880280
pii: 13993003.01991-2018
doi: 10.1183/13993003.01991-2018
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Imipenem
71OTZ9ZE0A
Azithromycin
83905-01-5
Amikacin
84319SGC3C
Clarithromycin
H1250JIK0A
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright ©ERS 2019.
Déclaration de conflit d'intérêts
Conflict of interest: N. Kwak has nothing to disclose. Conflict of interest: M.P. Dalcolmo has nothing to disclose. Conflict of interest: C.L. Daley reports grants and personal fees from Insmed, and personal fees from Horizon, Spero and Johnson and Johnson, outside the submitted work. Conflict of interest: G. Eather has nothing to disclose. Conflict of interest: R. Gayoso has nothing to disclose. Conflict of interest: N. Hasegawa reports grants and personal fees from Insmed Inc., during the conduct of the study; grants from Nikon Corporation, Taisho-Toyama Pharmaceutical Co., Ltd, Eisai Co., Ltd, Daiichi Sankyo Co., Ltd, MSD KK a subsidiary of Merck & Co. Inc., Sumitomo Dainippon Pharma Co., Ltd, Pfizer Inc., Astellas Pharma Inc., Cepheid Inc., Precision System Science Co., Ltd, and Medical and Biological Laboratories Co., Ltd, outside the submitted work. Conflict of interest: B.W. Jhun has nothing to disclose. Conflict of interest: W-J. Koh has received a consultation fee from Insmed Inc. for the Insmed advisory board meeting, not associated with the submitted work. Conflict of interest: H. Namkoong has nothing to disclose. Conflict of interest: J. Park has nothing to disclose. Conflict of interest: R. Thomson reports personal fees for advisory board work from Insmed and Savara, and personal fees for CME talks from Menarini and AstraZeneca, outside the submitted work. Conflict of interest: J. van Ingen reports personal fees for advisory board membership from Insmed, Spero Therapeutics and Johnson & Johnson, during the conduct of the study. Conflict of interest: S.M.H. Zweijpfenning reports personal fees and nonfinancial support from Insmed and Novartis outside the submitted work. Conflict of interest: J-J. Yim has nothing to disclose.